At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed, newly diagnosed, unilateral primary NSCLC
- ✓Disease must involve superior sulcus, chest wall, or mediastinum
- ✓Locally advanced Pancoast tumors (T3-T4, N0-1) with no documented mediastinal or supraclavicular nodal involvement
- ✓Resectable chest wall disease (T3, N0-1)
- ✕Evidence of extrathoracic spread to liver, adrenals, brain, or bone
- ✕Supraclavicular node involvement
- ✕Malignant pleural or pericardial effusions
- ✕Distant metastases
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Trimodality Protocol for the Treatment of Locally Advanced, Potentially Resectable Non-Small Cell Lung Cancer Targeting
In Brief
A Phase 2 clinical trial evaluating carboplatin, paclitaxel, and 2 other interventions for Lung Cancer. Completed, enrolled 19 participants across 1 site.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving combination chemotherapy with radiation therapy before and after surgery may shrink the tumor so it can be removed during surgery and may kill any remaining tumor cells following surgery. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel and carboplatin with radiation therapy and surgery in treating patients who have newly diagnosed locally advanced non-small cell lung cancer.